Immunovant (IMVT) moved lower on Thursday, April 2, 2026 after disclosing topline results from two Phase 3 (GO) studies evaluating batoclimab in adults with active, moderate-to-severe thyroid eye disease (TED). The company said the studies did not meet the pre-specified primary endpoint tied to proptosis (eye bulging) response at Week 24, a central efficacy metric in TED trials. The market is treating the miss as a meaningful setback for the batoclimab TED opportunity and for near-term pipeline de-risking.

For a clinical-stage biotech, late-stage trial outcomes are the highest-impact catalysts, and Phase 3 misses typically reset probability-of-success assumptions and peak-sales expectations. The miss also shifts attention away from batoclimab as a potential near-term value driver and toward IMVT-1402, Immunovant’s next-generation FcRn program. Investors are also recalibrating timing, because Immunovant has framed late-stage IMVT-1402 milestones as further out, with key registrational/late-stage topline data expected in 2027.

Traders will look for more granular trial details beyond the topline headline, including subgroup performance, durability, and any evidence that the dosing strategy (high-dose vs lower-dose maintenance) may have influenced outcomes. Investors will also watch for updated capital allocation and development prioritization across IMVT-1402 indications, including Graves’ disease as a stated priority. Any formal decision to discontinue, pause, or redesign batoclimab development in TED could further influence sentiment, alongside any guidance changes around the 2027 IMVT-1402 readout window.